Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Saved in:
| Title: | Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. |
|---|---|
| Authors: | Safyan RA; University of Washington School of Medicine, Seattle, WA, 98195, United States.; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States., White RA; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States., Gonda TA; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States., Lee SM; Columbia University Mailman School of Public Health, New York, NY, 10032, United States., Han J; Columbia University Mailman School of Public Health, New York, NY, 10032, United States., Kuriakose N; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States.; Department of Medicine, James J. Peters Bronx VA Medical Center, Bronx, NY, 10468, United States., Yamamoto NK; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States., Kugel S; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States., Jamison JK; Weill Medical College, Cornell University, New York, NY, 10065, United States., Manji GA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States., Schwartz GJ; Case Comprehensive Cancer Center, Cleveland, OH, 44106, United States., Oberstein PE; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States., Bates SE; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States.; Department of Medicine, James J. Peters Bronx VA Medical Center, Bronx, NY, 10468, United States. |
| Source: | The oncologist [Oncologist] 2026 Mar 09; Vol. 31 (4). |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyag091 |
